Total Payments
$59,369
2024 Payments
$2,225
Companies
6
Transactions
50
Medicare Patients
152
Medicare Billing
$23,201
Payment Breakdown by Category
Research$55,075 (92.8%)
Consulting$2,100 (3.5%)
Travel$1,352 (2.3%)
Food & Beverage$766.62 (1.3%)
Education$76.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $55,075 | 30 | 92.8% |
| Consulting Fee | $2,100 | 1 | 3.5% |
| Travel and Lodging | $1,352 | 6 | 2.3% |
| Food and Beverage | $766.62 | 11 | 1.3% |
| Education | $76.00 | 2 | 0.1% |
Payments by Type
Research
$55,075
30 transactions
General
$4,294
20 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $44,786 | 22 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $13,360 | 14 | $0 (2018) |
| Eisai Inc. | $1,003 | 10 | $0 (2017) |
| Novo Nordisk Inc | $125.00 | 1 | $0 (2024) |
| Genentech, Inc. | $76.00 | 2 | $0 (2019) |
| Allergan Inc. | $18.80 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,225 | 2 | Eli Lilly and Company ($2,100) |
| 2023 | $5,349 | 2 | Eli Lilly and Company ($5,349) |
| 2022 | $20,840 | 3 | Eli Lilly and Company ($20,840) |
| 2021 | $79.00 | 2 | Eli Lilly and Company ($79.00) |
| 2020 | $507.50 | 2 | Eli Lilly and Company ($507.50) |
| 2019 | $151.00 | 3 | Genentech, Inc. ($76.00) |
| 2018 | $28,423 | 22 | Eli Lilly and Company ($15,063) |
| 2017 | $1,795 | 14 | Eisai Inc. ($1,003) |
All Payment Transactions
50 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/12/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 03/01/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $300.00 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
| 01/10/2023 | Eli Lilly and Company | — | — | In-kind items and services | $5,048.92 | Research |
| Study: A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $660.00 | Research |
| Study: ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $450.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 04/08/2022 | Eli Lilly and Company | — | — | In-kind items and services | $19,730.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 08/20/2021 | Eli Lilly and Company | — | — | In-kind items and services | $29.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 06/30/2021 | Eli Lilly and Company | — | — | In-kind items and services | $50.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 07/31/2020 | Eli Lilly and Company | — | — | In-kind items and services | $270.00 | Research |
| Study: ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | ||||||
| 07/31/2020 | Eli Lilly and Company | — | — | In-kind items and services | $237.50 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 01/26/2019 | Genentech, Inc. | Non-Covered Product (Drug) | Education | In-kind items and services | $38.00 | General |
| Category: None | ||||||
| 01/26/2019 | Genentech, Inc. | Non-Covered Product (Drug) | Education | In-kind items and services | $38.00 | General |
| Category: None | ||||||
| 01/15/2019 | Eli Lilly and Company | — | — | In-kind items and services | $75.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 12/21/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $2,175.03 | Research |
| Study: ACP-103-046 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/20/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $8,605.36 | Research |
| Study: ACP-103-046 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/07/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $720.00 | Research |
| Study: ACP-103-046 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 10/23/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $112.00 | Research |
| Study: ACP-103-046 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 06/07/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | In-kind items and services | $340.77 | Research |
| Study: ACP-103-046 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 06/07/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | In-kind items and services | $340.77 | Research |
| Study: ACP-103-047 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 06/07/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | In-kind items and services | $272.50 | Research |
| Study: ACP-103-046 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 06/07/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | In-kind items and services | $272.50 | Research |
| Study: ACP-103-047 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 06/07/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | In-kind items and services | $209.09 | Research |
| Study: ACP-103-046 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 06/07/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | In-kind items and services | $209.09 | Research |
| Study: ACP-103-047 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 06/07/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | In-kind items and services | $40.62 | Research |
| Study: ACP-103-046 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $19,759 | 2 |
| A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $12,505 | 3 |
| ACP-103-046 | ACADIA Pharmaceuticals Inc | $12,486 | 9 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $5,049 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $2,134 | 3 |
| ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | Eli Lilly and Company | $930.00 | 2 |
| ACP-103-047 | ACADIA Pharmaceuticals Inc | $873.88 | 5 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $500.00 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $300.15 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $300.00 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $237.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 2 | 29 | 71 | $13,050 | $8,896 |
| 2020 | 4 | 123 | 224 | $36,700 | $14,305 |
Total Patients
152
Total Services
295
Medicare Billing
$23,201
Procedure Codes
6
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 14 | 46 | $8,050 | $5,223 | 64.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 15 | 25 | $5,000 | $3,673 | 73.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 46 | 110 | $16,500 | $6,912 | 41.9% |
| 90836 | Psychotherapy, 45 minutes | Office | 2020 | 43 | 62 | $12,400 | $4,542 | 36.6% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 22 | 37 | $5,550 | $2,302 | 41.5% |
| 99307 | Subsequent nursing facility visit, typically 10 minutes per day | Facility | 2020 | 12 | 15 | $2,250 | $549.72 | 24.4% |
About Dr. John Duffy, MD
Dr. John Duffy, MD is a Psychiatry healthcare provider based in Santa Ana, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255497251.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Duffy, MD has received a total of $59,369 in payments from pharmaceutical and medical device companies, with $2,225 received in 2024. These payments were reported across 50 transactions from 6 companies. The most common payment nature is "" ($55,075).
As a Medicare-enrolled provider, Duffy has provided services to 152 Medicare beneficiaries, totaling 295 services with total Medicare billing of $23,201. Data is available for 2 years (2020–2021), covering 6 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Santa Ana, CA
- Active Since 12/28/2006
- Last Updated 03/15/2023
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1255497251
Products in Payments
- NUPLAZID (Drug) $13,360
- Non-Covered Product (Drug) $76.00
- NAMZARIC (Drug) $18.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Santa Ana
Dr. Thomas Okamoto, M.d, M.D
Psychiatry — Payments: $11,777
Psychiatry $11,777
Dr. Huong Ngo, M.d, M.D
Psychiatry — Payments: $8,416
Psychiatry $8,416
Dr. My Luong, Md, MD
Psychiatry — Payments: $3,762
Psychiatry $3,762
Dr. Serge Abdishoo, M.d, M.D
Psychiatry — Payments: $3,067
Psychiatry $3,067
Dr. Christopher Heitland, M.d, M.D
Psychiatry — Payments: $2,148
Psychiatry $2,148
Geoffrey Phillips, M.d, M.D
Psychiatry — Payments: $1,226
Psychiatry $1,226